Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 191Magnetic Resonance Spectroscopy 141Biopsy 102pembrolizumab 82Carboplatin 76Cisplatin 68Nivolumab 62Radiotherapy 51Paclitaxel 51Gemcitabine 50Cyclophosphamide 48Dexamethasone 46durvalumab 39Radiation 39atezolizumab 36Pemetrexed 36olaparib 34Rituximab 34venetoclax 33Etoposide 33Doxorubicin 32Lenalidomide 31X-Rays 30Prednisone 30Bevacizumab 30Docetaxel 28Disulfides 28Immunoglobulin G 27Vincristine 26Ipilimumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × guadecitabine × 30 days × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02998567 2026-05-12

HyPeR

Royal Marsden NHS Foundation Trust

Phase 1 Active not recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡